stoxline Quote Chart Rank Option Currency Glossary
ProQR Therapeutics N.V. (PRQR)
1.8  0 (0%)    07-19 13:50
Open: 1.8
High: 1.8499
Volume: 19,768
Pre. Close: 1.8
Low: 1.8
Market Cap: 147(M)
Technical analysis
2024-07-19 1:22:20 PM
Short term     
Mid term     
Targets 6-month :  2.21 1-year :  2.59
Resists First :  1.89 Second :  2.21
Pivot price 1.73
Supports First :  1.72 Second :  1.61
MAs MA(5) :  1.81 MA(20) :  1.71
MA(100) :  1.97 MA(250) :  1.79
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  69.5 D(3) :  74.6
RSI RSI(14): 52.8
52-week High :  3.28 Low :  1.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PRQR ] has closed below upper band by 28.7%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.85 - 1.86 1.86 - 1.87
Low: 1.77 - 1.79 1.79 - 1.8
Close: 1.78 - 1.8 1.8 - 1.82
Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Headline News

Thu, 18 Jul 2024
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World

Tue, 18 Jun 2024
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK

Wed, 29 May 2024
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher - Simply Wall St

Sat, 11 May 2024
ProQR Therapeutics (PRQR) Stock Forecast and Price Target 2024 - MarketBeat

Thu, 09 May 2024
ProQR Announces First Quarter 2024 Operating and Financial Results - GlobeNewswire

Fri, 19 Apr 2024
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 82 (M)
Shares Float 58 (M)
Held by Insiders 18.8 (%)
Held by Institutions 39 (%)
Shares Short 197 (K)
Shares Short P.Month 232 (K)
Stock Financials
EPS -0.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.43
Profit Margin -254.3 %
Operating Margin -173.3 %
Return on Assets (ttm) -14.9 %
Return on Equity (ttm) -56.8 %
Qtrly Rev. Growth 568.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.12
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow 4 (M)
Stock Valuations
PE Ratio -5.01
PEG Ratio 0
Price to Book value 4.18
Price to Sales 13.92
Price to Cash Flow -3.84
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android